INTRODUCTION AND OBJECTIVES: Biguanides were originally developed for the treatment of hyperglycemia and type 2 diabetes mellitus. Recently, the biguanides metformin and phenformin have been shown to exert potential anticancer effects in prostate cancer. We evaluated the anti-cancer efficacy and mechanism of IM176, a novel biguanide derivate drug on prostate cancer using prostate cancer cell lines and patient-derived castration-resistant prostate cancer cell lines.
METHODS: Cell viability assay, annexin V-FITC apoptosis detection, microscopy with immunofluorescence staining, real-time quantitative reverse transcription-polymerase chain reaction, and western blotting were conducted. Efficacy of IM176 was also evaluated using 2 cell lines derived from castration-resistant prostate cancer patient.
RESULTS: IM176 dose-dependently inhibited cell viability in all prostate cancer cell lines at lowest IC50 concentrations (LNCaP: 18.5mM, 22Rv1: 36.8 mM) compared to those of metformin, and phenformin. IM176-mediated AMPK activation caused mTOR inhibition, and a decrement in the phosphorylation of p70S6K1 and S6. IM176 inhibited the expression of AR, AR-splice variant 7 (AR-V7) and prostate-specific antigen in LNCaP and 22Rv1. IM176 induced apoptosis with increased levels of cleavage of caspase-3, and annexin V-positive / PI-positive, respectively. Moreover, IM176 inhibited cell viability at lowest IC50 concentrations in 2 cell lines derived from castration-resistant prostate cancer patient. We evaluate the relationship between AMPK-mTOR pathway and AR signaling pathway by blocking each pathway separately. After AR knockdown, phosphorylation of AMPK was significantly increased. However, AR and AR-V7 were not increased after treating AMPK inhibitor, Compound C.
CONCLUSIONS: IM176 showed comparable anti-tumor effects via AMPK-mTOR pathway and AR signaling pathway with the lowest IC50 compared to other biguanide derivative drugs in prostate cancer cell lines, including patient-derived castration resistant prostate cancer cell line and may be a novel anti-cancer drug for the treatment of prostate cancer.
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MP64-09 IN SILICO SCREENING USING RNA-SEQ DATA SETS OF NEUROENDOCRINE PROSTATE CANCER HAS IDENTIFIED CANDIDATE DRUGS FOR REPROGRAMMING NEPC-SPECIFIC SIGNATURES.
Takeo Kosaka*, Hiroshi Hongo, Shuji Mikami, Kazuhiro Matsumoto, Eiji Kikuchi, Mototsugu Oya, Tokyo, Japan INTRODUCTION AND OBJECTIVES: Neuroendocrine prostate cancer (NEPC) is an aggressive subtype of castration-resistant prostate cancer (CRPC). The development of effective therapeutic strategies that can achieve improvement in patients with NEPC is urgently needed. In this study, we investigated NGS profiles in NEPC, CRPC or castration sensitive PC to identify candidate drugs with the potential to convert CRPC-NE properties into CRPC-adeno by in silico screenings RNA-seq data.
METHODS: We analyzed RNA-seq data of NEPC and CRPC, and compared using the Broad Institute's Connectivity Map (CMAP) to identify candidate drugs with the potential to revert tumors' NE properties. In drug screening system, we examined cell proliferation for these candidate drugs in human PCa cell lines of CSPC, CRPC, NEPC including LNCaP, C4-2, C4-2AT6, PC3, DU145, NCI-H660. The efficacy was determined in vitro and in vivo by cell viability assay, qPCR, Western Blot, Immunohistochemistry and xenograft tumor bering model.
RESULTS: In silico screening using RNA-seq data sets of NEPC and NCH-H660 allowed us to identify candidate 22 drugs for reprogramming NEPC-specific signatures into CRPC-adeno signatures. Among the listed drugs, we identified THM166 had significantly higher anti-tumor effect in NCI-H660 cells than other cell lines. In NCI-H660, the relative cell viability after treatment with 10 nM or 100 nM THM166 was 71.6 AE 1.2 % and 41.5 AE 0.9 %, respectively. On the other hand, THM166 did not have anti-tumor effect in other CRPC cell lines at the same dose, suggesting the specific selectivility of THM166 for NEPC cells. We investigated the expression of NEPC-related markers of Nmyc, synaptophigin and chromogranin in NCH-H660 cells by qPCR and Western blot (WB) analysis. qPCR and WB analysis revealed THM166 inhibited the expression of NEPC-related markers in a dose dependent manner. We examined the time course changes in NEPC tumor growth using NCI-H660 with THM166. In the controls, the ratio of tumor size on day 10 to day 1 was 192% (p<0.01). In contrast, the ratio of tumor size was 106% in the THM166 monotherapy groups(p<0.01). These results indicate that THM166 has a significant antitumor effect in NCI-H660 in vivo, as well as in vitro.
CONCLUSIONS: We identified a candidate drug: THM166 that can convert NEPC signature in CRPC one through reprograming the Nmyc related transdifferentiation. We propose THM166 as a potential drug for NEPC. . 199, No. 4S, Supplement, Sunday, May 20, 2018 THE JOURNAL OF UROLOGY â e853
